These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

224 related articles for article (PubMed ID: 17418005)

  • 1. Appearance of rheumatoid nodules following anti-tumor necrosis factor alpha treatment with adalimumab for rheumatoid arthritis.
    Scrivo R; Spadaro A; Iagnocco A; Valesini G
    Clin Exp Rheumatol; 2007; 25(1):117. PubMed ID: 17418005
    [No Abstract]   [Full Text] [Related]  

  • 2. Efficacy of rituximab on pulmonary nodulosis occurring or increasing in patients with rheumatoid arthritis during anti-TNF-α therapy.
    De Stefano R; Frati E; Nargi F; Menza L
    Clin Exp Rheumatol; 2011; 29(4):752-3. PubMed ID: 21906436
    [No Abstract]   [Full Text] [Related]  

  • 3. Development of rheumatoid nodules during anti-tumor necrosis factor alpha therapy with etanercept.
    Kekow J; Welte T; Kellner U; Pap T
    Arthritis Rheum; 2002 Mar; 46(3):843-4. PubMed ID: 11920425
    [No Abstract]   [Full Text] [Related]  

  • 4. Risk of serious infections and malignancies with anti-TNF antibody therapy in rheumatoid arthritis.
    Hochman D; Wolff B
    JAMA; 2006 Nov; 296(18):2203; author reply 2203-4. PubMed ID: 17090763
    [No Abstract]   [Full Text] [Related]  

  • 5. Risk of serious infections and malignancies with anti-TNF antibody therapy in rheumatoid arthritis.
    Callegari PE; Schaible TF; Boscia JA
    JAMA; 2006 Nov; 296(18):2202; author reply 2203-4. PubMed ID: 17090762
    [No Abstract]   [Full Text] [Related]  

  • 6. Risk of serious infections and malignancies with anti-TNF antibody therapy in rheumatoid arthritis.
    Costenbader KH; Glass R; Cui J; Shadick N
    JAMA; 2006 Nov; 296(18):2201; author reply 2203-4. PubMed ID: 17090761
    [No Abstract]   [Full Text] [Related]  

  • 7. Alopecia areata universalis during treatment of rheumatoid arthritis with anti-TNF-alpha antibody (adalimumab).
    Chaves Y; Duarte G; Ben-Said B; Tebib J; Berard F; Nicolas JF
    Dermatology; 2008; 217(4):380. PubMed ID: 18849606
    [No Abstract]   [Full Text] [Related]  

  • 8. Adalimumab-induced neutropenia in a patient with rheumatoid arthritis.
    Ottaviani S; Cerf-Payrastre I; Kemiche F; Pertuiset E
    Joint Bone Spine; 2009 May; 76(3):312-3. PubMed ID: 19289296
    [No Abstract]   [Full Text] [Related]  

  • 9. Secondary syphilis following tumor necrosis factor-α inhibitor treatment for rheumatoid arthritis.
    Asahina A; Ishii N; Tohma S
    J Dermatol; 2012 Feb; 39(2):199-201. PubMed ID: 21463364
    [No Abstract]   [Full Text] [Related]  

  • 10. Risk of serious infections and malignancies with anti-TNF antibody therapy in rheumatoid arthritis.
    Okada SK; Siegel JN
    JAMA; 2006 Nov; 296(18):2201-2; author reply 2203-4. PubMed ID: 17090760
    [No Abstract]   [Full Text] [Related]  

  • 11. Onset of systemic lupus erythematosus after conversion of infliximab to adalimumab treatment in rheumatoid arthritis with a pre-existing anti-dsDNA antibody level.
    van Rijthoven AW; Bijlsma JW; Canninga-van Dijk M; Derksen RH; van Roon JA
    Rheumatology (Oxford); 2006 Oct; 45(10):1317-9. PubMed ID: 16844698
    [No Abstract]   [Full Text] [Related]  

  • 12. Adalimumab-induced asthma.
    Bennett AN; Wong M; Zain A; Panayi G; Kirkham B
    Rheumatology (Oxford); 2005 Sep; 44(9):1199-200. PubMed ID: 15870147
    [No Abstract]   [Full Text] [Related]  

  • 13. Risk of herpes zoster in patients with rheumatoid arthritis treated with anti-TNF-alpha agents.
    Strangfeld A; Listing J; Herzer P; Liebhaber A; Rockwitz K; Richter C; Zink A
    JAMA; 2009 Feb; 301(7):737-44. PubMed ID: 19224750
    [TBL] [Abstract][Full Text] [Related]  

  • 14. CNS demyelination during anti-tumor necrosis factor alpha therapy.
    Bellesi M; Logullo F; Di Bella P; Provinciali L
    J Neurol; 2006 May; 253(5):668-9. PubMed ID: 16311894
    [No Abstract]   [Full Text] [Related]  

  • 15. Pyoderma gangrenosum in a patient with seronegative rheumatoid arthritis during therapy with adalimumab: toxic effects of adalimumab or failure of adalimumab to prevent the onset of this phenomenon?
    Stichenwirth M; Riedl E; Pehamberger H; Tappeiner G
    Arch Dermatol; 2008 Jun; 144(6):817-8. PubMed ID: 18559788
    [No Abstract]   [Full Text] [Related]  

  • 16. Pseudolymphomatoid cutaneous leishmaniasis in a patient treated with adalimumab for rheumatoid arthritis.
    Baltà-Cruz S; Alsina-Glbert M; Mozos-Rocafort A; Cervera C; Colomo-Saperas L; Del Río A; Estrach-Panella T
    Acta Derm Venereol; 2009; 89(4):432-3. PubMed ID: 19688168
    [No Abstract]   [Full Text] [Related]  

  • 17. Kaposi's disease in a patient on adalimumab for rheumatoid arthritis.
    Bret J; Hernandez J; Aquilina C; Zabraniecki L; Fournie B
    Joint Bone Spine; 2009 Dec; 76(6):721-2. PubMed ID: 19945327
    [No Abstract]   [Full Text] [Related]  

  • 18. A comparison of safety profiles of tumour necrosis factor α inhibitors and rituximab therapy in patients with rheumatoid arthritis and chronic hepatitis C.
    Chen YM; Chen HH; Chen YH; Hsieh TY; Hsieh CW; Hung WT; Lan JL; Chen DY
    Ann Rheum Dis; 2015 Mar; 74(3):626-7. PubMed ID: 25452310
    [No Abstract]   [Full Text] [Related]  

  • 19. Miller-Fisher syndrome in a patient with rheumatoid arthritis treated with adalimumab.
    Kurmann PT; Van Linthoudt D; So AK
    Clin Rheumatol; 2009 Jan; 28(1):93-4. PubMed ID: 18818868
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Dermatomyositis in patients with rheumatoid arthritis during adalimumab therapy.
    Nagashima T; Minota S
    J Rheumatol; 2011 Mar; 38(3):574; author reply 575. PubMed ID: 21362792
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 12.